Agnes Azimzadeh received her Ph.D. in Molecular and Cellular Biology and Immunology from the Institute of Molecular and Cellular Biology of the University Louis Pasteur in Strasbourg, France (1992), with a thesis on the measurement of antibody affinity. Her post-doctoral training at the Institute of Transplantation in Strasbourg (1993-99) included multiple national (eg, with Pr. Jean-Paul Soulillou's team in Nantes) and international collaborations. She then joined efforts with Richard Pierson at Vanderbilt University, before moving with him to the University of Maryland in Baltimore in 2002, and finally joining the Massachusetts General Hospital in Boston in 2018.
Agnes Azimzadeh has been involved in xenotransplantation since 1994, with collaborative studies including the evaluation of hDAF expressing rat hearts with Ignacio Anegon, the characterization of xenoreactive antibodies and assessment of vWF-GPIb axis in coagulation dysregulation by using organs from vWF deficient swine with Prof. Soulillou and Dr. Jean-Pierre Cazenave. Mentored by Dr. Pierson, a Past President of IXA, she is emerging as an independent researcher in the field, particularly in accurate measurement of anti-non-Gal antibody responses, characterization of coagulation pathway dysregulation in a variety of xenogeneic models, and identifying other innate immune mechanisms that contribute to injury of the lung and other organs following xenotransplantation. She is a regular contributor to the biennial IXA Congress, and an Associate Editor of Xenotransplantation, the Association’s official journal. She was Scientific Program Committee Chair for the Baltimore meeting of IXA. Elected as a member of the IXA Council in 2011, she served as Councilor for two years, Secretary-Treasurer for four years, and is the current President-Elect of the Association.
|Scientific Program Committee||Member|